Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body MyositisAnthony A. Amato, John Vissing, Hector Chinoy et al.|Neurology|2021Cited by 37
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trialPedro Machado, Sarah Heintzman, Michael McDermott et al.|The Lancet Neurology|2023Cited by 35